National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).

Rapid Review

Commenced Completed Outcome
07/04/2014 02/05/2014 Full Pharmacoeconomic Evaluation Not Recommended